Impact of epigenetics in the management of cardiovascular disease: A review

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 20, 2014, Pages 3097-3104

  Cao, Y ^a   Lu, L ^a   Liu, M ^a   Li, X C ^a   Sun, R R ^a   Zheng, Y ^a   Zhang, P Y ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Epigenetics; Histone; McroRNA

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOMOTIN LIKE PROTEIN 2; CD31 ANTIGEN; CYTOSINE; DNA; DNA BASE; HISTONE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; LONG UNTRANSLATED RNA; MICRORNA; PROTEIN; RHO GTPASE ACTIVATING PROTEIN 24; RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR TISSUE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONGENITAL HEART DISEASE; DNA HISTONE INTERACTION; DNA METHYLATION; DNA MODIFICATION; EMBRYO DEVELOPMENT; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; HEART FAILURE; HISTONE MODIFICATION; HUMAN; PROMOTER REGION; PROTEIN PROCESSING; REVIEW; VASCULITIS; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEART; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HEART; HUMANS; MICRORNAS;

EID: 84928679628     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. ANONYMOUS. Cardiovascular health for all. Lancet 2013; 382: 572
2. DUY GU B, POELS EM, DA COSTA MARTINS PA. Genetics and epigenetics of arrhythmia and heart failure. Front Genet 2013; 4: 219.
3. PAPAIT R, CONDORELLI G. Epigenetics in heart failure. Ann N Y Acad Sci 2010; 1188: 159-164.
4. OLSON EN, BACKS J, MCKINSEY TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 2006; 274: 3-12; discussion 13-19, 152-155, 272-156.
5. FEINBERG AP. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat Biotechnol 2010; 28: 1049-1052.
6. PORTELA A, ESTELLER M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-1068.
7. JAENISCH R, BIRD A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 Suppl: 245-254.
8. ELDER SJ, LICHTENSTEIN AH, PITTAS AG, ROBERTS SB, FUSS PJ, GREENBERG AS, MCCRORY MA, BOUCHARD TJ, JR., SALTZMAN E, NEALE MC. Genetic and environmental influences on factors associated with cardiovascular disease and the metabolic syndrome. J Lipid Res 2009; 50: 1917-1926.
9. FRAGA MF, BALLESTAR E, PAZ MF, ROPERO S, SETIEN F, BALLESTAR ML, HEINE-SUNER D, CIGUDOSA JC, URIOSTE M, BENITEZ J, BOIX-CHORNET M, SA NCHEZ-AGUILERA A, LING C, CARLSSON E, POULSEN P, VAAG A, STEPHAN Z, SPECTOR TD, WU YZ, PLASS C, ESTELLER M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2 005; 102: 10604-10609.
10. BEEKMAN M, NEDERSTIGT C, SUCHIMAN HE, KREMER D, VAN DER BREGGEN R, LAKENBERG N, ALEMAYEHU WG, DE CRAEN AJ, WESTENDORP RG, BOOMSMA DI, DE GEUS EJ, HOUWI NG-DUISTERMAAT JJ, HEIJMANS BT, SLAGBOOM PE. Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proc Natl Acad Sci U S A 2010; 107: 18046-18049.
11. WEBSTER AL, YAN MS, MARSDEN PA. Epigenetics and cardiovascular disease. Can J Cardiol 2013; 29: 46-57.
12. LISTER R, PELIZZOLA M, DOWEN RH, HAWKINS RD, HON G, TONTI-FILIPPINI J, NERY JR, LEE L, YE Z, NGO QM, EDSALL L, ANTOSIEWICZ-BOURGET J, STEWART R, RUOTTI V, MILLAR AH, THOMSON JA, REN B, ECKER JR. Human DNA methylomes at base resolution show widespread epigenomic differe nces. Nature 2009; 462: 315-322.
13. KIKUYAMA M, TAKESHIMA H, KINOSHITA T, OKOCHI-TAKADA E, WAKABAYASHI M, AKASHI-TANAKA S, OGAWA T, SETO Y, USHIJIMA T. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett 2012; 322: 204-212.
14. MATOUK CC, MARSDEN PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008; 102: 873-887.
15. MOVASSAGH M, CHOY MK, GODDARD M, BENNETT MR, DOWN TA, FOO RS. Differential DNA methylation correlates with differ ential expression of angiogenic factors in human heart failure. PLoS One 2010; 5: e8564.
16. MOVASSAGH M, CHOY MK, KNOWLES DA, CORDEDDU L, HAIDER S, DOWN T, SIGGENS L, VUJIC A, SI MEONI I, PENKETT C, GODDARD M, LIO P, BENNETT MR, FOO RS. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011; 124: 2411-2422.
17. MEURS KM, KUAN M. Differential methylation of CpG sites in two isoforms of myosin binding protein C, an important hypertrophic cardiomyopathy gene. Environ Mol Mutagen 2011; 52: 161-164.
18. BACCARELLI A, WRIGHT R, BOLLA TI V, LITONJUA A, ZANOBETTI A, TARANTINI L, SPARROW D, VOKONAS P, SCHWARTZ J. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010; 21: 819-828.
19. TALAULIKAR VS, ARULKUMARAN S. Folic acid in obstetric practice: a review. Obstet Gynecol Surv 2011; 66: 240-247.
20. YAN TT, LI Q, ZHANG XH, WU WK, SUN J, LI L, ZHANG Q, TAN HM. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/Akt/endothelial nitric oxide synthase signalling. Clin Exp Pharmacol Physiol 2010; 37: 1071-1077.
21. CEDAR H, BERGMAN Y. Programming of DNA methylation patterns. Annu Rev Biochem 2012; 81: 97-117.
22. LUND G, ANDERSSON L, LAURIA M, LINDHOLM M, FRAGA MF, VILLAR-GA REA A, BALLESTAR E, ESTELLER M, ZAINA S. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004; 279: 29147-29154.
23. K IM J, KIM JY, SONG KS, LEE YH, SEO JS, JELINEK J, GOLDSCHMIDT-CLERMONT PJ, ISSA JP. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 2007; 1772: 72-80.
24. KINNEY SM, CHIN HG, VAISVILA R, BITINAITE J, ZHENG Y, ESTEVE PO, FENG S, STROUD H, JACOBSEN SE, PRADHAN S. Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes. J Biol Chem 2011; 286: 24685-24693.
25. BARRICK CJ, ROBERTS RB, ROJAS M, RAJAMANNAN NM, SUITT CB, O'BRIEN KD, SMYTH SS, THREADGILL DW. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hyper trophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol 2009; 297: H65-75.
26. LENNARTSSON A, EKWALL K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta 2009; 1790: 863-868.
27. RODRIGUEZ JE, MCCUDDEN CR, WILLIS MS. Familial hypertrophic cardiomyopathy: Basic concepts and future molecular diagnostics. Clin Biochem 2009; 42: 755-765.
28. SHAHBAZIAN MD, GRUNSTEIN M. Functions of sitespecific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76: 75-100.
29. GUSTERSON RJ,JAZRAWI E,ADCOCK IM,LATCHMAN DS. The transcriptional co-Activators CREB-binding protein (CBP) and p300 play a critical role in cardiac h ypertrophy that is dependent on their histone acetyltransferase activity J Biol Chem 2003 278 6838-6847.
30. ABI KHALIL C. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis 2014; 5: 178-187.
31. CHANG S, MCKINSEY TA, ZHANG CL, RICHARDSON JA, HILL JA, OLSON EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in hear t development. Mol Cell Biol 2004; 24: 8467-8476.
32. TRIVEDI CM, LUO Y, YIN Z, ZHANG M, ZHU W, WANG T, FLOSS T, GOETTLICHER M, NOPPINGER PR, WURST W, FERRARI VA, ABRAMS CS, GRUBER PJ, EPSTEIN JA. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13: 324-331.
33. KANEDA R, TAKADA S, YAMASHITA Y, CHOI YL, NONAKASARUKAWA M, SODA M, MISAWA Y, ISOMURA T, SHIMADA K, MANO H. Genome-wide histone methylation profile for heart failure. Genes Cells 2009; 14: 69-77.
34. NGUYEN AT, ZHANG Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 25: 1345-1358.
35. KOOISTRA SM, HELIN K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13: 297-311.
36. ZHANG QJ, CHEN HZ, WANG L, LIU DP, HILL JA, LIU ZP. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest 2011; 121: 2447-2456.
37. YAN MS, MATOUK CC, MARSDEN PA. Epigenetics of the vascular endothelium. J Appl Physiol (1985) 2010; 109: 916-926.
38. HO JJ, MAN HS, MARSDEN PA. Nitric oxide signaling in hypoxia. J Mol Med (Berl) 2012; 90: 217-231.
39. ZHANG L, QIN X, ZHAO Y, FAST L , ZHUANG S, LIU P, CHENG G, ZHAO TC. Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J Pharmacol Exp Ther 2012; 341: 285-293.
40. KHACHANE AN, HARRISON PM. Mining mammalian transcript data for functional long non-coding rnas. PLoS One 2010; 5: e10316.
41. KAIKKONEN MU, LAM MT, GLA SS CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 2011; 90: 430-440.
42. ESTELLER M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
43. BAUERSACHS J, THUM T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011; 109: 334-347.
44. CARE A, CATALUCCI D, FELICETTI F, BONCI D, ADDARIO A, GALLO P, BANG ML, SEGNALINI P, GU Y, DALTON ND, ELIA L, LATRONICO MV, HOYDAL M, AUTORE C, RUSSO MA, DORN GW, 2ND, ELLINGSEN O, RUIZ-LOZANO P, PETERSON KL, CROCE CM, PESCHLE C, CONDORELLI G. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-618.
45. LATRONICO MV, CONDORELLI G. MicroRNA and cardiac pathology. Nat Rev Cardiol 2009; 6: 419-429.
46. IKEDA S, KONG SW, LU J, BISPING E, ZHANG H, ALLEN PD, GOLUB TR, PIESKE B, PU WT. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31: 367-373.
47. BAGNALL RD, TSOUTSMAN T, SHEPHARD RE, RITCHIE W, SEMSARIAN C. Global MicroRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One 2012; 7: e44744.
48. BARRY SP, DAVIDSON SM, TOWNSEND PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 2008; 40: 2023-2039.
49. HAN P, HANG CT, YANG J, CHANG CP. Chromatin remodeling in cardiovascular development and physiology. Circ Res 2011; 108: 378-396.
50. STANKUNAS K,HANG CT,TSUN ZY,CHEN H,LEE NV,WU JI,SHANG C,BAYLE JH,SHOU W,IRUELA-ARISPE ML,CHANG CP. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis Dev Cell 2008 14 298-311.
51. WANG Z, ZHAI W, RICHARDSON JA, OLSON EN, MENESES JJ, FIRPO MT, KANG C, SKARNES WC, TJIAN R. Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. Genes Dev 2004; 18: 3106-3116.
52. HANG CT, YANG J, HAN P, CHENG HL, SHANG C, ASHLEY E, ZHOU B, CHANG CP. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 2010; 466: 62-67.